Joyant Pharmaceuticals

Joyant Pharmaceuticals was a Dallas-based biotechnology company focused on the discovery and development of small molecule therapeutics for the treatment of cancer. The company's primary research centered on the Wnt signaling pathway, specifically developing inhibitors of Tankyrase enzymes. Founded based on research from the University of Texas Southwestern Medical Center, Joyant aimed to address unmet needs in oncology through novel mechanism-of-action drugs. In 2009, the company was acquired by Genentech, a member of the Roche Group, to integrate its Tankyrase inhibitor program into Genentech's oncology pipeline. The acquisition highlighted the industry's interest in targeting the Wnt pathway, which is frequently dysregulated in various cancers, including colorectal cancer.